Linny Kimly Phuong1, Caterina Bonetto2, Jim Buttery3, Yolanda Brauchli Pernus4, Rebecca Chandler5, Patrizia Felicetti2, Karen L Goldenthal6, Merita Kucuku7, Giuseppe Monaco8, Barbara Pahud9, Stanford T Shulman10, Karina A Top11, Francesco Trotta2, Rolando Ulloa-Gutierrez12, Frederick Varricchio13, Sarah de Ferranti14, Jane W Newburger14, Nagib Dahdah15, Surjit Singh16, Jan Bonhoeffer17, David Burgner18. 1. Monash Children's Hospital, Clayton, Melbourne, Australia; Royal Children's Hospital, Parkville, Victoria, Australia. 2. Italian Medicines Agency (AIFA), Rome, Italy. 3. Monash Children's Hospital, Clayton, Melbourne, Australia; Murdoch Childrens Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, Monash University, Clayton, Victoria, Australia. 4. The Brighton Collaboration Foundation, Basel, Switzerland. 5. Uppsala Monitoring Centre, Uppsala, Sweden. 6. Independent Consultant, Bethesda, MD, USA. 7. Department of Vaccines Control, National Agency for Medicines and Medical Devices, Tirana, Albania. 8. Pharmacovigilance Regional Centre of Lombardy, Italy. 9. Children's Mercy Hospital, Kansas City, MO, USA. 10. Ann & Robert H. Lurie Children's Hospital of Chicago, USA. 11. Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada. 12. Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera, San José, Costa Rica. 13. Independent Consultant Vaccinologist, Wakefield, RI, USA. 14. Boston Children's Hospital, Boston, USA. 15. CHU Sainte-Justine, Montreal, Canada. 16. Post Graduate Institute of Medical Education and Research (PGIMER)- Chandigarh, India. 17. The Brighton Collaboration Foundation, Basel, Switzerland; University of Basel Children's Hospital, Basel, Switzerland. Electronic address: contact@brightoncollaboration.org. 18. Monash Children's Hospital, Clayton, Melbourne, Australia; Murdoch Childrens Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, Monash University, Clayton, Victoria, Australia; Department of Paediatrics, Melbourne University, Parkville, Victoria, Australia.
Abstract
BACKGROUND: Kawasaki disease is a complex and potentially serious condition. It has been observed in temporal relation to immunisation. METHODS: We conducted a systematic literature review using various reference sources to review the available evidence published in the literature. RESULTS: We identified twenty seven publications reporting a temporal association between immunisation and Kawasaki disease. We present a systematic review of data drawn from randomised controlled trials, observational studies, case series and reports, and reviews. Overall there was a lack of standardised case definitions, making data interpretation and comparability challenging. CONCLUSIONS: Although a temporal relationship between immunisation and Kawasaki disease is suggested, evidence for an increased risk or a causal association is lacking. Implementation of a standardised Kawasaki disease case definition would increase confidence in the findings and add value to future studies of pre- or post-licensure vaccine safety studies.
BACKGROUND:Kawasaki disease is a complex and potentially serious condition. It has been observed in temporal relation to immunisation. METHODS: We conducted a systematic literature review using various reference sources to review the available evidence published in the literature. RESULTS: We identified twenty seven publications reporting a temporal association between immunisation and Kawasaki disease. We present a systematic review of data drawn from randomised controlled trials, observational studies, case series and reports, and reviews. Overall there was a lack of standardised case definitions, making data interpretation and comparability challenging. CONCLUSIONS: Although a temporal relationship between immunisation and Kawasaki disease is suggested, evidence for an increased risk or a causal association is lacking. Implementation of a standardised Kawasaki disease case definition would increase confidence in the findings and add value to future studies of pre- or post-licensure vaccine safety studies.
Authors: Chi Yon Seo; Mohammed Rashid; Tara Harris; Jody Stapleton; Shelley L Deeks Journal: Paediatr Child Health Date: 2019-04-08 Impact factor: 2.253
Authors: Tiphanie P Vogel; Karina A Top; Christos Karatzios; David C Hilmers; Lorena I Tapia; Pamela Moceri; Lisa Giovannini-Chami; Nicholas Wood; Rebecca E Chandler; Nicola P Klein; Elizabeth P Schlaudecker; M Cecilia Poli; Eyal Muscal; Flor M Munoz Journal: Vaccine Date: 2021-02-25 Impact factor: 3.641
Authors: Anne E Wormsbecker; Caitlin Johnson; Laura Bourns; Tara Harris; Natasha S Crowcroft; Shelley L Deeks Journal: PLoS One Date: 2019-01-15 Impact factor: 3.240